-
(Nowak
JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep
2006;58:353–63.16845209)
Nowak
JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep
2006;58:353–63.16845209
Nowak
JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep
2006;58:353–63.16845209, Nowak
JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep
2006;58:353–63.16845209
-
(Arnold
JJ, Markey
CM, Kurstjens
NP, et al. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmol
2016;16:31. 10.1186/s12886-016-0207-327009515)
Arnold
JJ, Markey
CM, Kurstjens
NP, et al. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmol
2016;16:31. 10.1186/s12886-016-0207-327009515
Arnold
JJ, Markey
CM, Kurstjens
NP, et al. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmol
2016;16:31. 10.1186/s12886-016-0207-327009515, Arnold
JJ, Markey
CM, Kurstjens
NP, et al. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmol
2016;16:31. 10.1186/s12886-016-0207-327009515
-
C.
Wykoff,
W.
Clark,
J.
Nielsen,
J.
Brill,
L.
Greene,
Cherilyn
Heggen
(2018)
Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration
Journal of Managed Care & Specialty Pharmacy, 24
-
(Ho
AC, Busbee
BG, Regillo
CD, et al. HARBOR Study Group. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology
2014;121:2181–92. 10.1016/j.ophtha.2014.05.00925015215)
Ho
AC, Busbee
BG, Regillo
CD, et al. HARBOR Study Group. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology
2014;121:2181–92. 10.1016/j.ophtha.2014.05.00925015215
Ho
AC, Busbee
BG, Regillo
CD, et al. HARBOR Study Group. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology
2014;121:2181–92. 10.1016/j.ophtha.2014.05.00925015215, Ho
AC, Busbee
BG, Regillo
CD, et al. HARBOR Study Group. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology
2014;121:2181–92. 10.1016/j.ophtha.2014.05.00925015215
-
(Wykoff
CC, Clark
WL, Nielsen
JS, et al. Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration. J Manag Care Spec Pharm
2018;24:S3–15. 10.18553/jmcp.2018.24.2-a.s3)
Wykoff
CC, Clark
WL, Nielsen
JS, et al. Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration. J Manag Care Spec Pharm
2018;24:S3–15. 10.18553/jmcp.2018.24.2-a.s3
Wykoff
CC, Clark
WL, Nielsen
JS, et al. Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration. J Manag Care Spec Pharm
2018;24:S3–15. 10.18553/jmcp.2018.24.2-a.s3, Wykoff
CC, Clark
WL, Nielsen
JS, et al. Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration. J Manag Care Spec Pharm
2018;24:S3–15. 10.18553/jmcp.2018.24.2-a.s3
-
(2005)
Polish Academy of Sciences Review
-
(Chakravarthy
U, Havilio
M, Syntosi
A, et al. Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD. Eye
2021;35:2983–90. 10.1038/s41433-020-01354-433414525)
Chakravarthy
U, Havilio
M, Syntosi
A, et al. Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD. Eye
2021;35:2983–90. 10.1038/s41433-020-01354-433414525
Chakravarthy
U, Havilio
M, Syntosi
A, et al. Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD. Eye
2021;35:2983–90. 10.1038/s41433-020-01354-433414525, Chakravarthy
U, Havilio
M, Syntosi
A, et al. Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD. Eye
2021;35:2983–90. 10.1038/s41433-020-01354-433414525
-
(Busbee
BG, Ho
AC, Brown
DM, et al. HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology
2013;120:1046–56. 10.1016/j.ophtha.2012.10.01423352196)
Busbee
BG, Ho
AC, Brown
DM, et al. HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology
2013;120:1046–56. 10.1016/j.ophtha.2012.10.01423352196
Busbee
BG, Ho
AC, Brown
DM, et al. HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology
2013;120:1046–56. 10.1016/j.ophtha.2012.10.01423352196, Busbee
BG, Ho
AC, Brown
DM, et al. HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology
2013;120:1046–56. 10.1016/j.ophtha.2012.10.01423352196
-
U.
Chakravarthy,
Moshe
Havilio,
A.
Syntosi,
Natasha
Pillai,
E.
Wilkes,
Gidi
Benyamini,
C.
Best,
A.
Sagkriotis
(2021)
Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD
Eye, 35
-
T.
Wong,
U.
Chakravarthy,
R.
Klein,
P.
Mitchell,
G.
Zlateva,
R.
Buggage,
K.
Fahrbach,
C.
Probst,
I.
Sledge
(2008)
The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis.
Ophthalmology, 115 1
-
J.
Arnold,
C.
Markey,
N.
Kurstjens,
R.
Guymer
(2016)
The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study
BMC Ophthalmology, 16
-
(Evans
RN, Reeves
BC, Maguire
MG, et al. Associations of variation in retinal thickness with visual acuity and anatomic outcomes in eyes with neovascular age-related macular degeneration lesions treated with anti-vascular endothelial growth factor agents. JAMA Ophthalmol
2020;138:1043–51. 10.1001/jamaophthalmol.2020.300132816002)
Evans
RN, Reeves
BC, Maguire
MG, et al. Associations of variation in retinal thickness with visual acuity and anatomic outcomes in eyes with neovascular age-related macular degeneration lesions treated with anti-vascular endothelial growth factor agents. JAMA Ophthalmol
2020;138:1043–51. 10.1001/jamaophthalmol.2020.300132816002
Evans
RN, Reeves
BC, Maguire
MG, et al. Associations of variation in retinal thickness with visual acuity and anatomic outcomes in eyes with neovascular age-related macular degeneration lesions treated with anti-vascular endothelial growth factor agents. JAMA Ophthalmol
2020;138:1043–51. 10.1001/jamaophthalmol.2020.300132816002, Evans
RN, Reeves
BC, Maguire
MG, et al. Associations of variation in retinal thickness with visual acuity and anatomic outcomes in eyes with neovascular age-related macular degeneration lesions treated with anti-vascular endothelial growth factor agents. JAMA Ophthalmol
2020;138:1043–51. 10.1001/jamaophthalmol.2020.300132816002
-
B.
Busbee,
A.
Ho,
David
Brown,
J.
Heier,
I.
Suñer,
Zhengrong
Li,
Roman
Rubio,
Phillip
Lai
(2013)
Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
Ophthalmology, 120 5
-
(Ohr
M, Kaiser
PK. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin Pharmacother
2012;13:585–91. 10.1517/14656566.2012.65836822300011)
Ohr
M, Kaiser
PK. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin Pharmacother
2012;13:585–91. 10.1517/14656566.2012.65836822300011
Ohr
M, Kaiser
PK. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin Pharmacother
2012;13:585–91. 10.1517/14656566.2012.65836822300011, Ohr
M, Kaiser
PK. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin Pharmacother
2012;13:585–91. 10.1517/14656566.2012.65836822300011
-
P.
Jong
(2004)
Prevalence of age-related macular degeneration in the United States.
Archives of Ophthalmology, 122
-
(Lanzetta
P, Loewenstein
A, Vision Academy Steering Committee. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol
2017;255:1259–73. 10.1007/s00417-017-3647-428527040)
Lanzetta
P, Loewenstein
A, Vision Academy Steering Committee. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol
2017;255:1259–73. 10.1007/s00417-017-3647-428527040
Lanzetta
P, Loewenstein
A, Vision Academy Steering Committee. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol
2017;255:1259–73. 10.1007/s00417-017-3647-428527040, Lanzetta
P, Loewenstein
A, Vision Academy Steering Committee. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol
2017;255:1259–73. 10.1007/s00417-017-3647-428527040
-
Matthew
Ohr,
P.
Kaiser
(2012)
Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration
Expert Opinion on Pharmacotherapy, 13
-
(Jhaveri
CD, Dugel
PU, Wykoff
CC. Visual and anatomic outcomes for brolucizumab and aflibercept in patients with nAMD: 96-week data from hawk and harrier. American Society of Retina Specialists Annual Meeting; 26–30 July, Chicago, IL, 2019.)
Jhaveri
CD, Dugel
PU, Wykoff
CC. Visual and anatomic outcomes for brolucizumab and aflibercept in patients with nAMD: 96-week data from hawk and harrier. American Society of Retina Specialists Annual Meeting; 26–30 July, Chicago, IL, 2019.
Jhaveri
CD, Dugel
PU, Wykoff
CC. Visual and anatomic outcomes for brolucizumab and aflibercept in patients with nAMD: 96-week data from hawk and harrier. American Society of Retina Specialists Annual Meeting; 26–30 July, Chicago, IL, 2019., Jhaveri
CD, Dugel
PU, Wykoff
CC. Visual and anatomic outcomes for brolucizumab and aflibercept in patients with nAMD: 96-week data from hawk and harrier. American Society of Retina Specialists Annual Meeting; 26–30 July, Chicago, IL, 2019.
-
U.
Schmidt-Erfurth,
V.
Chong,
A.
Loewenstein,
M.
Larsen,
E.
Souied,
R.
Schlingemann,
B.
Eldem,
J.
Monés,
G.
Richard,
F.
Bandello
(2014)
Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
The British Journal of Ophthalmology, 98
-
(Schmidt-Erfurth
U, Chong
V, Loewenstein
A, et al. European Society of Retina Specialists. Guidelines for the management of neovascular age-related macular degeneration by the European Society of retina specialists (EURETINA). Br J Ophthalmol
2014;98:1144–67. 10.1136/bjophthalmol-2014-30570225136079)
Schmidt-Erfurth
U, Chong
V, Loewenstein
A, et al. European Society of Retina Specialists. Guidelines for the management of neovascular age-related macular degeneration by the European Society of retina specialists (EURETINA). Br J Ophthalmol
2014;98:1144–67. 10.1136/bjophthalmol-2014-30570225136079
Schmidt-Erfurth
U, Chong
V, Loewenstein
A, et al. European Society of Retina Specialists. Guidelines for the management of neovascular age-related macular degeneration by the European Society of retina specialists (EURETINA). Br J Ophthalmol
2014;98:1144–67. 10.1136/bjophthalmol-2014-30570225136079, Schmidt-Erfurth
U, Chong
V, Loewenstein
A, et al. European Society of Retina Specialists. Guidelines for the management of neovascular age-related macular degeneration by the European Society of retina specialists (EURETINA). Br J Ophthalmol
2014;98:1144–67. 10.1136/bjophthalmol-2014-30570225136079
-
(Dhoot
DS, Kaiser
PK. Ranibizumab for age-related macular degeneration. Expert Opin Biol Ther
2012;12:371–81. 10.1517/14712598.2012.66052322309606)
Dhoot
DS, Kaiser
PK. Ranibizumab for age-related macular degeneration. Expert Opin Biol Ther
2012;12:371–81. 10.1517/14712598.2012.66052322309606
Dhoot
DS, Kaiser
PK. Ranibizumab for age-related macular degeneration. Expert Opin Biol Ther
2012;12:371–81. 10.1517/14712598.2012.66052322309606, Dhoot
DS, Kaiser
PK. Ranibizumab for age-related macular degeneration. Expert Opin Biol Ther
2012;12:371–81. 10.1517/14712598.2012.66052322309606
-
(Wong
TY, Wong
T, Chakravarthy
U, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology
2008;115:116–26. 10.1016/j.ophtha.2007.03.00817675159)
Wong
TY, Wong
T, Chakravarthy
U, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology
2008;115:116–26. 10.1016/j.ophtha.2007.03.00817675159
Wong
TY, Wong
T, Chakravarthy
U, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology
2008;115:116–26. 10.1016/j.ophtha.2007.03.00817675159, Wong
TY, Wong
T, Chakravarthy
U, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology
2008;115:116–26. 10.1016/j.ophtha.2007.03.00817675159
-
Visual and anatomic outcomes for brolucizumab and aflibercept in patients with nAMD : 96 - week data from hawk and harrier
-
(Friedman
DS, O'Colmain
BJ, Muñoz
B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol
2004;122:564–72. 10.1001/archopht.122.4.56415078675)
Friedman
DS, O'Colmain
BJ, Muñoz
B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol
2004;122:564–72. 10.1001/archopht.122.4.56415078675
Friedman
DS, O'Colmain
BJ, Muñoz
B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol
2004;122:564–72. 10.1001/archopht.122.4.56415078675, Friedman
DS, O'Colmain
BJ, Muñoz
B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol
2004;122:564–72. 10.1001/archopht.122.4.56415078675
-
D.
Dhoot,
P.
Kaiser
(2012)
Ranibizumab for age-related macular degeneration
Expert Opinion on Biological Therapy, 12
-
A.
Ho,
B.
Busbee,
C.
Regillo,
M.
Wieland,
Sherri
Everen,
Zhengrong
Li,
Roman
Rubio,
Phillip
Lai
(2014)
Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
Ophthalmology, 121 11
-
JZ
Nowak
(2006)
Age-related macular degeneration (AMD): pathogenesis and therapy
, 58
-
P.
Lanzetta,
A.
Loewenstein
(2017)
Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti–vascular endothelial growth factor therapy of macular diseases
Graefe's Archive for Clinical and Experimental Ophthalmology, 255
-
R.
Evans,
B.
Reeves,
M.
Maguire,
Daniel
Martin,
A.
Muldrew,
T.
Peto,
C.
Rogers,
U.
Chakravarthy
(2020)
Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti–Vascular Endothelial Growth Factor Agents
JAMA Ophthalmology, 138